Related Experiment Video
Updated: Aug 11, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
[Synergism of PGI2 and molsidomine in arterial occlusive disease]
1Wilhelm Auerswald-Atheroskleroseforschungsgruppe (ASF) Wien, Osterreich.
Abstract:
In order to test the hypothesis, whether molsidomine acts as an in-vivo NO-donor, we examined the synergism of PGI2 and molsidomine in patients with peripheral vascular disease. The effect was quantified by measuring the platelet uptake at atherosclerotic lesion sites, as well as measuring the platelet survival after radiolabelling the autologous platelets with 111Indium-oxine. The combination of both substances achieved a significantly higher (p less than 0.01) benefit in comparison to single administration of either of the components. This synergism was shown via a decrease in thrombogenicity and a prolongation in platelet survival. These data indicate that a potentiating synergism of hemostatic regulation can be achieved via an in-vivo interaction between NO and PGI2.
More Related Videos
Related Concept Videos
Nitric Oxide Signaling Pathway
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peripheral Artery Disease III: Interprofessional Care

